No quarterly revenue total was found in Braveheart Bio, Inc.'s SEC filings.
Braveheart Bio, Inc. (BRVE) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$22.2 million. As of Jun 30, 2026 it held $122.8 million in cash and investments and $575,000 in total debt.
Revenue
—
Net income
$-14.99M
Operating cash flow
$-22.14M
Free cash flow
$-22.16M
EPS
$-2.51
Dividend per share
None
Shares outstanding
90.04M
Net cash
$122.26M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BRVE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2131524
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
|---|---|
| Operating income | -$15.9M |
| Net income | -$15.0M |
| Diluted EPS | -$2.51 |
| Operating cash flow | -$22.1M |
| Free cash flow | -$22.2M |
| Total assets | $127.0M |
| Total liabilities | $9.3M |
| Stockholders' equity | -$95.9M |
| Cash and investments | $122.8M |
| Total debt | $575,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 8, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 7, 2026 | Aug 5, 2026 |
All 47 Braveheart Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.